DGX Stock Recent News

Second quarter revenues of $2.76 billion, up 15.2% from 2024 Second quarter reported diluted earnings per share ("EPS") of $2.47, up 21.7% from 2024; and adjusted diluted EPS of $2.62, up 11.5% from 2024 Year-to-date cash provided by operations of $858 million, up 67.1% from 2024 Full year 2025 reported diluted EPS now expected to be between $8.60 and $8.80; and adjusted diluted EPS is expected to be between $9.63 and $9.83 SECAUCUS, N.J. , July 22, 2025 /PRNewswire/ -- Quest Diagnostics Incorporated (NYSE: DGX), a leading provider of diagnostic information services, today announced financial results for the second quarter ended June 30, 2025.

DGX is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Quest Diagnostics' Q2 results may get a lift from Advanced Diagnostics, new health plan deals and recent acquisitions.

Quest Diagnostics (DGX) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

Diagnostic testing for emerging infectious disease associated with severe neurological affects SECAUCUS, N.J. , July 15, 2025 /PRNewswire/ -- Quest Diagnostics (NYSE: DGX), a leader in diagnostic information services, today announced the launch of a new diagnostic laboratory test for the Oropouche virus, an emerging disease that is increasingly found in South and Central America and the Caribbean.

For my initial rating of Quest Diagnostics (DGX), I'm calling it a buy. Forecasts point to continuing demand for diagnostic testing, while the company also grew its business via acquisitions and new solutions. Strong profit margins, proven cashflow and dividend growth, and investment-grade credit ratings from major agencies are additional upside factors.

Test to be available for clinical and research use as soon as this summer, building on Quest's pioneering blood-based AD-Detect™ product line for assessing symptomatic patients SECAUCUS, N.J. , July 9, 2025 /PRNewswire/ -- Quest Diagnostics (NYSE: DGX), a leader in diagnostic information services, including advanced diagnostics for brain health, today announced it plans to offer laboratory testing based on the Lumipulse® G pTau 217/β-Amyloid 1-42 Plasma Ratio in-vitro diagnostic (IVD) test from Fujirebio, a global leader in the field of high-quality IVD testing.

DGX stock surges 27.3% in a year, fueled by Advanced Diagnostics, key acquisitions and expanding health plan ties.

An aging global population and AI dominance are likely to drive the Zacks Medical - Outpatient and Home Healthcare industry despite the macroeconomic challenges. DGX, EHC, DVA and PNTG are well-poised to gain.